However, it is of interest to note that STAT6 has been described as a signaling molecule downstream of Akt [41], [42], suggesting to us that these changes after receiving tremelimumab may be reflective of a specific pathway modulation leading to more effective tumor targeting and killing. The gene discussed is STAT6; the disease is neoplasm.